DANIEL LYNCH - 21 Oct 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Director, 10%+ Owner
Signature
/s/ Chris Frankenfield, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
21 Oct 2021
Net transactions value
$0
Form type
3
Filing time
21 Oct 2021, 20:39:43 UTC
Previous filing
18 Oct 2021
Next filing
17 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Stock Option (right to buy) 21 Oct 2021 Common Stock 134,797 $5.51 Direct F1
holding XLO Stock Option (right to buy) 21 Oct 2021 Common Stock 200,597 $5.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 23, 2020 for 134,797 shares. The underlying shares began vesting on June 11, 2020 and shall continue to vest in equal monthly installments thereafter until June 11, 2024.
F2 The option was granted on March 11, 2021 for 200,597 shares. The underlying shares began vesting on June 11, 2020 and shall continue to vest in equal monthly installments thereafter until June 11, 2024.

Remarks:

Exhibit Index: 24.1 Power of Attorney